Introduction: Although paclitaxel with carboplatin and thoracic radiotherapy has improved survival for patients with locally advanced unresectable non-small cell lung cancer (NSCLC), the optimal dose of paclitaxel has not been well defined in Japan. This study was conducted to determine the maximum tolerated dose Conclusions: This phase I study was well tolerated and the RD of paclitaxel and carboplatin with RTRT is 40 mg/m 2 at AUC=2, respectively. Further studies are warranted to evaluate the efficacy of this regimen.
Introduction
Lung cancer is a leading cause of malignancy-related death around the worldwide ([1]). Although the use of concurrent chemotherapy and radiotherapy has improved survival for patients with locally advanced unresectable non-small-cell lung cancer (NSCLC) over the last two decades, cure rates are still low and treatment-related toxicities remain concern ( [2] , [3] , [4] ).
Paclitaxel is a microtubular inhibitor and arrests cell cycle in the G2-M phase, which is well recognized as the most radiosensitive phase. Paclitaxel reportedly enhances the radiosensitivity of cells in vitro ( [5] ). Choy et al. reported that the maximum tolerated dose (MTD) of weekly paclitaxel with concurrent radiation was 60mg/m 2 in phase I ( [6] ) and 1-, 2-, and 3-year overall survival rates were 60.6%, 33.3%, and 18.2%, respectively ( [7] ). Moreover, they conducted a phase II study of paclitaxel at 50mg/m 2 , carboplatin at an area under the curve (AUC) of 2 and concurrent radiotherapy, revealing 1-and 2-year overall survival rates of 56.3% and 38.3%, respectively ([8] ). In Japan, several phase I trials of paclitaxel, carboplatin (AUC=2) and radiotherapy have been conducted. Endo et al. reported that the MTD of paclitaxel was 45 mg/m 2 and dose limiting toxicity (DLT) was pulmonary toxicity ( [9] ). Based on these results, the recommended dose (RD) of paclitaxel was considered to be 35-40 mg/m 2 in
Japan. Compared to the results from the United States, the dose of paclitaxel remains low and has not been well investigated.
Shirato et al. developed a real-time tumor-tracking radiation therapy
(RTRT) which increases the potential efficacy of radiation by reducing the volume of normal tissue irradiated ( [10] ). We have reported the feasibility of thoracic RTRT with insertion of gold markers into or near peripheral lung cancers using bronchoscopy. Local tumor response was achieved and maintained for 12 of 13 patients, with a median follow-up of 9 months ( [11] ). Although radiation-induced pneumonitis was found in most of the patients with RTRT, these patients were asymptomatic. Moreover, RTRT with insertion of gold markers into the submucosal layer of the esophagus using endoscopy has also been shown to be feasible for the monitoring of the esophagus at risk ( [12] , [13] ).
Taken together, we hypothesized that use of the RTRT system with concurrent paclitaxel and carboplatin might reduce radiation-induced toxicities including radiation-pneumonitis and esophagitis, potentially allowing dose escalation of paclitaxel.
This phase I study investigated concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced NSCLC to evaluate feasibility and to determine the MTD and RD of paclitaxel.
Materials and Methods

Patient eligibility
This phase I study was approved by the ethics committee at Hokkaido University School of Medicine. All subjects gave written informed consent prior to enrolling in this study. Three patients were enrolled at the first dose level, and in the absence of DLTs, three patients were entered to the next dose level. If one of 3 patients developed a DLT, then three additional patients were enrolled at the same level.
If more than 1 of 3 or more than 2 of 6 patients had DLTs at a specific dose level, that dose level was defined as the maximum tolerated dose (MTD). The
Recommended Dose (RD) was determined as the dose level that is one level bellow the MTD.
Radiotherapy
The procedures for insertion of gold markers have been provided previously ( [11] ). Before radiotherapy, gold markers were inserted into the lung and the mediastinum of all patients using bronchoscopy and gastric endoscopy.
RTRT began concurrently on day 1 with chemotherapy for all patients for 7
weeks. Gating was done for all patients. The setup of the RTRT system has been described previously ( [10, 13] ). Same method was used in this clinical trial. toxicities. If these toxicities were resolved, radiotherapy was reinstituted.
Results
Eight patients (6 men, 2 women) were enrolled on this study between ). The first and second patients experienced no DLTs. However, the third patient showed grade 3 esophagitis and required intravenous infusion, which was considered a DLT. The percentage of total esophageal volume treated to >50 Gy (V50) has been identified as a significant predictor of acute esophagitis and it was reported that rates of acute severe esophagitis increased in patients with esophageal V50 >40% ( [15] ). V50 of this patient was 39.1%, which was relatively predictive of esophageal toxicity. One patient with larger V50 (67.1%) had grade 2 esophagitis and other 6 patients without grade 2/3 esophagitis had smaller V50 than 32.2%.
Two more patients were thus added at Level 2. No DLT was observed in the fourth patient. The fifth patient discontinued chemotherapy for 2 weeks due to persistent grade 3 leucopenia, which was considered as a DLT. The fifth patient was removed from the protocol and received radiotherapy alone. Grade 3 radiation pneumonitis developed in this patient 1 month after radiotherapy was finished. Patients with V20 >30% reportedly encountered severe radiation pneumonitis ( [16] , [17] ). V20 was 34% in this patient, which was predicted as the high risk of radiation pneumonitis, whereas, V20 was less than 20% in other 7
patients.
In summary, 2 of 5 patients at Level 2 experienced DLTs. Although enrollment of one additional patient was required to determine MTD, radiation pneumonitis in the fifth patient was severe, and the safety monitoring committee considered that the additional enrollment was difficult. Finally, the MTD and RD of paclitaxel were determined to be 45 mg/m 2 and 40 mg/m 2 , respectively. No treatment-related deaths were encountered in this study.
Treatment response
All patients were assessable for treatment response (Table 4 ). Five of all eight patients showed partial response (PR), 2 had stable disease (SD), and 1 experienced progressive disease (PD). The patient with PD was the fifth patient at Level 2. This patient received chemotherapy only twice because of DLT and was removed from the protocol. Radiotherapy alone was continued but brain metastasis was found soon after radiotherapy was completed, resulting in treatment response being categorized as PD.
Discussion
We conducted a phase I study of paclitaxel, carboplatin and concurrent radiation using RTRT system in patients with locally unresectable advanced escalation of paclitaxel in a phase I study due to concern over radiation pneumonitis [9] . One patient developed grade 3 pneumonitis in the present study: but that symptom was not considered a DLT because the pneumonitis occurred after the defined period for DLT estimation. However, we stopped additional patient enrollment to ensure safety. Finally, the MTD of paclitaxel in this study was determined as 45 mg/m 
